ValiRx plc - Asset Resilience Ratio

Latest as of June 2002: 6.92%

ValiRx plc (VAL) has an Asset Resilience Ratio of 6.92% as of June 2002. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ValiRx plc (VAL) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

£241.00K

≈ $323.64K USD Cash + Short-term Investments

Total Assets

£3.48 Million

≈ $4.68 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2001–2017)

This chart shows how ValiRx plc's Asset Resilience Ratio has changed over time. See VAL net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ValiRx plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VAL company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	£0.00	0%
Short-term Investments	£241.00K	6.92%
Total Liquid Assets	£241.00K	6.92%

Asset Resilience Insights

Limited Liquidity: ValiRx plc maintains only 6.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ValiRx plc Industry Peers by Asset Resilience Ratio

Compare ValiRx plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for ValiRx plc (2001–2017)

The table below shows the annual Asset Resilience Ratio data for ValiRx plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2017-12-31	2.37%	£117.23K ≈ $157.43K	£4.94 Million ≈ $6.63 Million	-0.46pp
2016-12-31	2.84%	£140.68K ≈ $188.91K	£4.96 Million ≈ $6.66 Million	-25.73pp
2015-12-31	28.57%	£1.46 Million ≈ $1.96 Million	£5.12 Million ≈ $6.88 Million	+2.19pp
2001-12-31	26.38%	£425.00K ≈ $570.74K	£1.61 Million ≈ $2.16 Million	--

pp = percentage points

About ValiRx plc

LSE:VAL UK Biotechnology

Market Cap

$279.27 Million

£207.96 Million GBP

Market Cap Rank

#29179 Global

#584 in UK

Share Price

£0.28

Change (1 day)

+0.00%

52-Week Range

£0.24 - £0.75

All Time High

£3312.50